Ruxolitinib for the treatment of myelofibrosis: its clinical potential

Alen Ostojic
Radovan Vrhovac
Srdan Verstovsek

Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Abstract: Ruxolitinib is an orally bioavailable, selective Janus kinase (JAK) 1 and 2 inhibitor approved for the treatment of myelofibrosis (MF), a bone marrow disease in which the JAK pathway is dysregulated, leading to impaired hematopoiesis and immune function. By inhibiting JAK1 and JAK2, ruxolitinib modulates cytokine-stimulated intracellular signaling. In a phase II clinical trial in patients with MF, ruxolitinib recipients exhibited durable reductions in spleen size, reductions in circulating pro-inflammatory cytokines, improvements in physical activity, weight gain, and alleviation of symptoms (including constitutional symptoms) in patients with and without JAK2 mutation. These findings were confirmed by two phase III clinical MF studies, in which a greater proportion of ruxolitinib recipients achieved a spleen volume reduction of $35\%$ from baseline at week 24, compared with placebo in one study (41.9\% versus 0.7\%; $P < 0.0001$) and with best available therapy in the other (31.9\% versus 0\%; $P < 0.0001$). Alleviation of MF symptoms and improvements in quality of life were also significantly greater in ruxolitinib recipients. Overall survival of patients treated with ruxolitinib was significantly longer than of those receiving the placebo. Owing to risks of potentially serious adverse effects, eg, myelosuppression, ruxolitinib should be used under close physician supervision. Longer follow-up of the phase III MF studies is needed to reach firm conclusions regarding ruxolitinib’s capacity to modify the natural disease course.

Keywords: myelofibrosis, JAK2 inhibitor, ruxolitinib

Introduction

Myelofibrosis (MF) is a bone marrow disease characterized by excessive production of reticulin and collagen fibers. Although fibrosis can be the outcome of numerous hematologic and nonhematologic conditions,\(^1\) the term MF is commonly used in reference either to primary MF (PMF)\(^2\) or to the similar disorders evolving from the two other classic Philadelphia-chromosome-negative myeloproliferative neoplasms: polycythemia vera (post-PV MF) and essential thrombocythemia (post-ET MF).\(^3\)

According to epidemiological studies,\(^4\)–\(^9\) the incidence of PMF may be as high as 1.5 per 100,000. Other studies\(^10\)–\(^14\) show that by the end of the second decade after PV or ET diagnosis, up to 10\%–15\% of cases may transform to secondary MF.

In MF, the fibrotic changes appear to be cytokine-stimulated reactions sustained by multineutropoiesis: clonal cellular proliferation.\(^15\)–\(^21\) The clinical signs of MF include splenomegaly due to extramedullary hematopoiesis; leukocytosis and thrombocytosis, with predisposition to thrombotic events, due to clonal cellular proliferation affecting mainly megakaryocytes and granulocytes; cytophenias, a later finding that worsens with the progression of fibrosis; and constitutional symptoms (eg, fatigue, weight
Therapeutics and Clinical Risk Management 2012:8

loss, low-grade fever, night sweats), most likely induced by abnormal levels of circulating cytokines.

In the past decade, the role of Janus kinases (JAKs) in intracellular pathways has claimed the attention of many myeloproliferative neoplasm researchers. JAKs are non-receptor tyrosine kinases that mediate the transmission of cytokine- and growth-factor-induced intracellular signals (Figure 1). About 50% of patients with PMF present with the JAK2^V617F gain-of-function mutation, resulting in a constitutively activated JAK-signal transducer and activator of transcription (JAK-STAT) pathway. In turn, the activated JAK-STAT pathway promotes the transcription of numerous genes, eg, for cytokines, fibrogenic factors, and angiogenic factors, among a broad variety of pro-proliferative and anti-apoptotic gene products. Excessive production of pro-inflammatory cytokines may itself contribute to JAK-STAT activation, creating a vicious cycle. Among patients with MF, about 5% are JAK2^V617F-negative but instead have a gain-of-function mutation in the thrombopoietin receptor gene (MPL^W515L mutation), resulting in cytokine-independent JAK-STAT activation. Another small group of patients with MF have neither of these mutations but carry other

mutations (e.g., in lymphocyte adaptor protein CBL) associated with constitutive JAK2 activation. Moreover, patients with MF in the absence of any identified mutation often exhibit JAK2 overactivity. JAK1 also plays a role in MF: a recent study demonstrated JAK1 hyperactivity in MF patients, most likely as a consequence of cytokine hyperstimulation. Collectively, these data implicate JAK1 and JAK2 as important pieces in the puzzle posed by the molecular pathogenesis of MF.

Currently, the only potentially curative treatment for MF is allogeneic hematopoietic stem cell transplantation, an option traditionally feasible only for a small subgroup of patients, the younger and physically fit, although new reports suggest its utility in the older patients as well.[35,36] Other treatment modalities (e.g., hydroxyurea, anagrelide, splenectomy or splenic irradiation, lenalidomide or thalidomide with or without corticosteroids, transfusions, danazol, androgens) are only palliative and without a substantial influence on survival.[37-53] Patients often die from bone marrow failure accompanied by systemic infection or fatal hemorrhage.[20,54,55] However, with the discovery of the JAK2(V617F) mutation,[56-59] JAK2 emerged as a potential target for treatment, and several small-molecule, ATP-competitive JAK2 inhibitors were developed (SAR302503 [TG101348], lestaurtinib [CEP-701], XL019, SB1518, CYT387, AZD1480, and ruxolitinib).[60-63] Ruxolitinib (formerly known as INCB018424) is the first and currently the only JAK inhibitor approved by the US Food and Drug Administration or any other regulatory agency for treatment of patients with MF,[64] and clinical development of several JAK inhibitors (SAR302503 [TG101348], CYT387, and LY278544) is ongoing. Although not as developed as ruxolitinib, available data on the efficacy of the other JAK2 inhibitors suggests similar profiles, mainly reduction in the size of enlarged organs (splenomegaly and hepatomegaly) and elimination of MF-related symptoms. The differences among them so far are mainly seen in relation to their toxicity profiles, eg, a degree of myelosuppression, gastrointestinal and/or neurological side effects.

**Preclinical studies of ruxolitinib**

Ruxolitinib phosphate (Figure 2) is an orally administered ATP-competitive cyclopentylpropionitrile derivative. In preclinical studies, it showed inhibitory activity in vitro mainly against JAK1 (IC$_{50}$ = 3.3 nM) and JAK2 (IC$_{50}$ = 2.8 nM).[30] Moderate to minimal inhibitory activity was observed against nonreceptor tyrosine kinase TYK2 (half-maximal inhibitory concentration [IC$_{50}$] = 19 nM) and against JAK3 (IC$_{50}$ = 428 nM), as well as minimal inhibitory activity against multiple other kinases at concentrations about 100-fold higher than the IC$_{50}$ for JAK1/2.[30] Selectivity against JAK1/2 was confirmed by measurements of STAT activity in a cytokine-stimulated whole-blood assay.[30]

In an engineered cell system containing growth-factor-independent JAK2(V617F)-expressing Ba/F3 cells (Ba/F3-EpoR-JAK2(V617F)), ruxolitinib demonstrated a dose-dependent reduction of JAK2-mediated downstream phosphorylated proteins with no change in their total levels,[30] suggesting that ruxolitinib exerts its effect through achievement of reduced levels of phosphorylated (active) forms. A similar effect was observed in the HEL cell line.[30] In these cell lines and in cells from mononuclear PV patients, ruxolitinib demonstrated antiproliferative and proapoptotic effects.[30] Analogous effects were not observed on BCR-ABL-1 signaling or in a cell line expressing an activating mutation in c-KIT.[30] The effects of ruxolitinib were attenuated when cells expressing JAK2(V617F) were cocultured with primary or immortalized human bone marrow mesenchymal cells.

**Table 1** Examples of strong cytochrome P450 3A4 inhibitors with potential influence on the pharmacokinetics of coadministered ruxolitinib[71,72]

<table>
<thead>
<tr>
<th>Drug</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketoconazole</td>
<td><em>Observed interaction</em></td>
</tr>
<tr>
<td>Itraconazole</td>
<td><em>Observed interaction</em></td>
</tr>
<tr>
<td>Posaconazole</td>
<td></td>
</tr>
<tr>
<td>Voriconazole</td>
<td></td>
</tr>
<tr>
<td>Clarithromycin</td>
<td></td>
</tr>
<tr>
<td>Telithromycin</td>
<td></td>
</tr>
<tr>
<td>Azacitidine</td>
<td></td>
</tr>
<tr>
<td>Indinavir</td>
<td></td>
</tr>
<tr>
<td>Nelfinavir</td>
<td></td>
</tr>
<tr>
<td>Ritonavir</td>
<td></td>
</tr>
<tr>
<td>Saquinavir</td>
<td></td>
</tr>
<tr>
<td>Nefazodone</td>
<td></td>
</tr>
</tbody>
</table>

**Figure 2** Ruxolitinib-phosphate, a chemical structure of orally available Janus kinase 1 and 2 inhibitor.
The pharmacokinetics and metabolism of ruxolitinib were established in early studies in healthy volunteers who received single doses of 25 mg or single or multiple ascending doses of 5 mg to as much as 200 mg. After a single oral dose, >95% of the drug is absorbed, and >97% of the absorbed drug becomes bound to plasma proteins. Plasma concentrations peak 1–3 hours after administration, with monophasic or biphasic decline. The terminal half-life is 2–3 hours. Administration of doses of up to 200 mg demonstrated dose-proportional exposure.

Ruxolitinib is metabolized predominantly in the liver, as a substrate of cytochrome P450 3A4 (CYP3A4), and its metabolites are mainly excreted in urine. There is no evidence of accumulation of either ruxolitinib or its metabolites. Factors that may influence the pharmacokinetics of ruxolitinib have been evaluated. A high-fat meal reduced the maximum plasma concentration by 24%, but had no substantial influence on bioavailability. Because of the routes by which ruxolitinib is metabolized and excreted, exposure may be increased in patients with impaired renal or hepatic function. When coadministered with rifampin (a CYP3A4 inducer), or erythromycin (a moderate CYP3A4 inhibitor), no changes in ruxolitinib pharmacokinetics were observed in healthy subjects. However, in healthy subjects who received ruxolitinib concomitantly with ketoconazole (a strong CYP3A4 inhibitor), the area under the curve increased by 91% and the half-life increased from 3.7 to 6.0 hours. There is a possibility of similar effects when ruxolitinib is coadministered with drugs that are strong inhibitors of CYP3A4 (Table 1).

### Safety across clinical trials

In healthy volunteers and in patients with MF, myelosuppression, and in particular thrombocytopenia, was the dose-limiting toxicity of ruxolitinib. The maximum tolerated dose was established as 25 mg twice daily (bid) and 100 mg once daily (qd). One healthy volunteer receiving a ruxolitinib dose of 50 mg/ bid developed high-grade neutropenia and recovered 12 days after ruxolitinib discontinuation. In phase I/II and III clinical trials in patients with MF, the most common hematologic adverse effects were thrombocytopenia and anemia (Table 2). Myelosuppression was dose-dependent and was not a frequent reason for withdrawal. Dose-dependent myelosuppression was not observed in a study of healthy volunteers. In the blinded, placebo-controlled phase III trial, the most frequent nonhematologic adverse events reported more commonly for ruxolitinib treatment than for placebo were ecchymosis, dizziness, and fatigue (mostly grade 1 or 2). Given the mechanism of action of ruxolitinib (JAK1/JAK2 inhibition), immunosuppression may be a possible adverse event; however, this was not observed to an appreciable extent in the clinical trials so far.

In a phase I/II clinical trial, investigators described clinical symptoms and signs suggesting development of systemic inflammatory response syndrome in two patients (1.3%) following sudden cessation of ruxolitinib. A similar reaction was not described among patients in two phase III clinical trials. Nevertheless, recently published phase I/II data from one center describe similar effects of abrupt cessation in four patients, and 2 weeks after cessation a
fifth patient developed a syndrome similar to disseminated intravascular coagulation with sequential severe polyarticular arthritis. Cytokine-rebound phenomena were suggested as mechanisms leading to “ruxolitinib discontinuation syndrome.” Apart from this one-center experience, such events have not been observed by other investigators in any other study (~170 clinical centers). However, to avoid any possibility of such complications, it is advisable to taper the dose when discontinuing ruxolitinib.78,79

**Efficacy in the phase I/II clinical trial of ruxolitinib in MF**

A phase I/II clinical trial of open-label ruxolitinib in MF (INCB018424-251; ClinicalTrials.gov, NCT00509899) was conducted at two United States centers: the MD Anderson Cancer Center in Houston, Texas and the Mayo Clinic in Rochester, Minnesota. In all, 153 patients (PMF 53%, post-PV MF 32%, and post-ET MF 15%) were enrolled, with a median age of 65 years (range, 40–84 years). On the Lille scoring system,80 65% of patients were at high risk, 28% at intermediate-2 risk, 7% at undetermined risk, and 82% were JAK2V617F-positive. In phase I of the study, a maximum tolerated dose and dose-limiting toxicity were identified.

In phase II, several dosing regimens, all below the maximum tolerated dose, were investigated. Among them, 15 mg/bid and 25 mg/bid regimens were identified as the most appropriate for optimal efficacy and minimal adverse effects. In 52% and 49% of the patients on these regimens (15 mg/bid and 25 mg/bid, respectively), ruxolitinib reduced palpable splenomegaly by ≥50% from baseline (the study’s predefined measure of clinical improvement) after three cycles of treatment (one cycle = 4 weeks of daily ruxolitinib). Among patients exhibiting this response, the response was maintained after 12 months of treatment in 73% of those on 15 mg/bid and 78% of those on 25 mg/bid. The 15 mg/bid regimen was associated with a lower incidence of grade 3 or 4 thrombocytopenia. In a subset of 24 patients in the 15 mg/bid group, change in spleen volume was evaluated by magnetic resonance imaging (MRI); the median reduction after six cycles of treatment was 33%, corresponding to a median 52% reduction in palpable spleen length. In the same MRI substudy, hepatomegaly decreased by 14% in six patients with hepatomegaly at baseline.

Patients also demonstrated improvement in other measures of disease burden. On a 6-minute walk test, as performed in 27 patients after 1, 3, and 6 months of treatment, median distances walked were 34, 57, and 71 m, respectively. Moreover, after a year of treatment, patients on 15 mg/bid and 25 mg/bid regimens gained weight; a median 9.4 and 7.1 kg, respectively. Ruxolitinib recipients with a body mass index in the lowest quartile at baseline had the most prominent weight gain. In general, improvements in performance status were maintained with therapy.

Ruxolitinib treatment also led to decreases in peripheral blood cell counts, including CD34-positive cells. In addition, peripheral blood cytokine levels (of interleukin-1 and tumor necrosis factor-α) decreased in association with improvement of symptoms, while plasma levels of leptin and erythropoietin increased. Thirty-four patients were available for evaluation of JAK2V617F allele burden reduction; the mean maximal suppression was modest (13% from baseline). However, a dose-dependent reduction of constitutively phosphorylated STAT3 and STAT5 was observed.

Recently, the two centers participating in this phase I/II clinical trial have published separate reports78,82,83 of their long-term experience in the treatment of patients with MF. For 51 ruxolitinib-treated patients enrolled in the trial between October 2007 and February 2009 inclusive, the Mayo Clinic in Rochester reported a high discontinuation rate: 51%, 72%, and 89% at 1, 2, and 3 years, respectively.78 As of October 2011, 18 patients (35%) had died and five patients (10%) had developed transformation to leukemia. Survival rate showed no significant difference between the ruxolitinib recipients and a cohort of 410 recipients of standard PMF treatment at their center during the past decade (P = 0.43).

In contrast, the MD Anderson Cancer Center reported that of 107 patients enrolled in the phase I/II trial, 58 (54%) were still receiving ruxolitinib at a median of 32 months.82 As of December 2011, 33 patients (31%) had died, 19 of them off-study and none for therapy-related reasons, and nine patients (8%) had developed transformation to leukemia, four of them off-study. By log-rank analysis, the survival of patients receiving ruxolitinib was significantly longer than in a historical cohort of 310 patients treated with standard or investigational therapy who would have met the phase I/II trial enrollment criteria (hazard ratio = 0.61, 95% CI: 0.41–0.89; P = 0.02).83 Survival of high-risk ruxolitinib recipients (of whom 21 of 63, or 33%, died) was also significantly longer (P = 0.006) than that of high-risk patients from the control group (of whom 112 of 165, or 68%, died). Patients continue to be followed. The outcome differences between the cohorts at the two centers are possibly related to the inferior efficacy of therapy at the Mayo Clinic in Rochester due to lower dosage and shorter duration (higher discontinuation rate) of therapy.83
Phase III clinical trials of ruxolitinib in MF

Two phase III clinical trials, the Controlled Myelofibrosis Study with Oral JAK1/JAK2 Inhibitor Treatment I and II (COMFORT-I76,77 AND COMFORT-II; ClinicalTrials.gov, NCT00952289 and NCT00934544, respectively), have been conducted and are still ongoing.

COMFORT-I is a double-blind, placebo-controlled study that enrolled 309 adults with MF in the United States, Canada, and Australia. Patients were randomized (1:1) to receive ruxolitinib or placebo. Based on baseline peripheral blood platelet count (Plt), the ruxolitinib was initiated at 15 mg/bid (Plt = 100–200 × 10⁹/L) or 20 mg/bid (Plt > 200 × 10⁹/L). Dose adjustment was allowed in accordance with efficacy and safety observations during the study, as defined by the protocol. At week 24, the median spleen volume reduction in ruxolitinib recipients was 40% and decreased to 10% in placebo recipients. 76,77 The same meaningful improvements in symptoms and QoL.87,88 Patients were randomized (2:1) to ruxolitinib or best available therapy (BAT). The ruxolitinib dose was 15 mg/bid or 20 mg/bid, based on the same Plt values as in COMFORT-I, and was subject to adjustment within the range of 5 mg/bid to 25 mg/bid. The BAT could be oral, parenteral, or no therapy. Spleen volume reductions of ≥35% (by MRI or computed tomography) at weeks 48 and 24 were the primary and key secondary endpoints, respectively. The primary endpoint was reached by 28.5% of ruxolitinib and 0% of BAT recipients (P < 0.0001), and the key secondary endpoint by 31.9% and 0% (P < 0.0001).75 Response rates were also higher for ruxolitinib than for BAT in subgroups based on JAK2 V617F mutational status, risk group, MF type, hydroxyurea pretreatment, baseline spleen size or volume, age, and sex.89

Symptoms measured by the EORTC QLQ-C30 showed significant improvements in the ruxolitinib group, starting at week 8, with continued improvement through week 48 versus BAT (P < 0.05).90 Similarly, mean subscores in the Functional Assessment of Cancer Therapy–Lymphoma System (FACT-LymS)91 improved with ruxolitinib treatment. No significant difference was found between risk-based subgroups of ruxolitinib recipients.

A post-hoc comparison of the COMFORT-I placebo and COMFORT-II BAT groups showed no significant difference in symptoms and QoL. In the placebo group, median spleen volume increased at week 24 by 8.5% (range, −46.4% to +48.8%) and in the BAT group by 5.1% (range, −33.3% to +29.7%).92

Conclusion

In clinical trials, ruxolitinib alleviated the burdensome manifestations of MF, namely splenomegaly and disease core symptoms. Patients experienced reductions in spleen size, decreases in circulating pro-inflammatory cytokines, increases in weight, and substantial improvements in symptoms and QoL. Based on the efficacy and tolerability reported in clinical trials, ruxolitinib became the first drug approved by the US Food and Drug Administration, in mid-November 2011, for the treatment of MF, and now has an important place among available treatment options. The reported data suggests that its effects are independent of patient characteristics including age, MF subtype, risk group, JAK2 V617F mutation status, baseline palpable spleen length, and baseline hemoglobin level. Although data from the COMFORT-I phase III clinical trial provides evidence that ruxolitinib prolongs the life of patients with advanced MF, ruxolitinib does not have a curative potential in the disease. On the other hand, ruxolitinib seems...
to offer significant and clinically meaningful benefit over other treatment modalities currently used when allogeneic hematopoietic stem cell transplantation is not an option. Also, it may become useful in pretreating patients deemed unfit for allogeneic hematopoietic stem cell transplantation, perhaps aiding them in becoming clinically fit for the transplant procedure. However, this would have to be proved in clinical trials. Due to potentially serious adverse effects, ruxolitinib should be used under close supervision of a physician. Follow-up data from the ruxolitinib phase III clinical trials, especially concerning long-term effects and survival, are needed to draw any stronger conclusions about its enduring benefits in MF. The next wave of clinical studies will explore the combination strategies in MF, by combining ruxolitinib with other active agents in this disease, eg, lenalidomide, danazol, erythropoietin, interferon, and others, with a goal to bring additional benefits to the JAK2 inhibitor therapy, like improvement in blood cell count and decrease in bone marrow fibrosis.

Disclosure
Professor S. Verstovsek has received research support from Incyte for the conduct of clinical studies. The other authors state no conflicts of interest.

References


